Please login to the form below
38
Revenue 2017Imbruvica
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Imbruvica was produced by Johnson & Johnson.
Roche pays $775m upfront to access Blueprint’s RET programme
to currently available BTK inhibitors, such as Johnson &Johnson’s Imbruvica (ibrutinib).
EU grants approval for Venclyxto/Gazyvaro combo in CLL
It also has to contend with the combination of AbbVie’s Imbruvica (ibrutinib) plus Gazyvaro, which became the first chemo-free option for first-line CLL therapy last year.
AZ revenues rise, but it says coronavirus could hit 2020
Recently-approved for a new chronic lymphocytic leukaemia (CLL) indication, AZ’s rival to Johnson &Johnson’s blockbuster BTK inhibitor Imbruvica (ibrutinib) – Calquence (acalabrutinib) – also gathered momentum and contributed $56m in
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma
Other treatment options for advanced MCL include BeiGene’s recently approved BTK inhibitor Brukinsa (zanubrutinib) and AbbVie/Johnson &Johnson’s established BTK inhibitor Imbruvica (ibrutinib).
Skyrizi, Rinvoq help AbbVie weather Humira slowdown
Outside its critical immunology franchise there were also gains for blood cancer therapy Imbruvica (ibrutinib), up almost 29% to $1.3bn, as well as a $251m contribution from newer therapy Venclexta
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Keytruda doubles five-year survival rate in NSCLC
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
OPEN Health
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
